Go to navigation Go to content
Toll-Free: 800-752-0042
Phone: 757-460-7776
Shapiro & Appleton

Swiss Regulators Mistakenly Keep Yaz and Yasmin on the Open Market

Comments (0)

Swissmedic, which oversees medical devices and medicines in Switzerland, made a questionable decision to leave Yaz and Yasmin on the open market for consumers to purchase. These dangerous drugs may have contributed to the death of a young woman and another woman who is now disabled, according to World Radio Switzerland.

Yaz, Yasmin, drug, medication, birth control, lawyer, injury, side effectsSwissmedic stated the risk of thrombosis (i.e. blood clot) is higher with Yaz and Yasmin, but the risk remains, as they say "within reasonable limits." I couldn't disagree more. A woman in her 20s having her gallbladder removed after taking these dangerous drugs is not "reasonable." A young woman suddenly suffering pancreatitis is not "reasonable."

Unfortunately, the Food and Drug Administration (the American equivalent to Swissmedic) appears to be making a similar error. Even after a wave of lawsuits have been filed against Bayer, the manufacturer of Yaz and Yasmin, by victims who have suffered serious side effects, these birth control pills are still available to the general public.

I believe the longer these hazardous birth control pills remain available to women the more victims will be created who suffer terrible Yaz and Yasmin side effects. The FDA needs to strongly consider taking them off the market.  

For more information about the dangers of Yaz and Yasmin, check out these articles and special reports:

Richard N. Shapiro
Personal Injury & Wrongful Death Lawyer Serving Va Beach, Norfolk, Chesapeake & all of Virginia
Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."

Name:*

Email:* (will not be published)

Message:*

Notify me of follow-up comments via email.

Avvo The Best lawyers in America Super lawyers Best Law Firms US News Verdicts and Settlements AV LexisNexis

Live Chat